Prescribing Cefixime in the absence of a proven or strongly suspected bacterial infection of a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
The possibility of the emergence of resistant organisms which might result in overgrowth should be kept in mind, particularly during prolonged treatment.
In such cases, careful observation of the patient is essential and if superinfection occurs during therapy appropriate measures should be taken.
The dose of Cefixime should be adjusted in patients with renal impairment as well as those undergoing continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD).
Patients on dialysis should be monitored carefully.
Cefixime should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.
Use in Children: Safety and Effectiveness of Cefixime in children aged less than 6 months have not been determined.
The incidence of gastrointestinal adverse reactions, including diarrhea and loose stools in pediatric patients receiving the suspension was comparable to the incidence seen in adult patients on tablets.
FC tab: Pseudomembraneous colitis has been reported with the use of Cefixime and other broad spectrum antibiotics including Macrolides, Semisynthetic Penicillins and Cephalosporins, therefore it is important to consider this diagnosis in patients who develop diarrhea in association with the use of antibiotics.
Symptoms of Pseudomembraneous Colitis may occur during or after antibiotic treatment and may range in severity from mild to life threatening.